WO2024254540A3 - Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition - Google Patents

Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition Download PDF

Info

Publication number
WO2024254540A3
WO2024254540A3 PCT/US2024/033123 US2024033123W WO2024254540A3 WO 2024254540 A3 WO2024254540 A3 WO 2024254540A3 US 2024033123 W US2024033123 W US 2024033123W WO 2024254540 A3 WO2024254540 A3 WO 2024254540A3
Authority
WO
WIPO (PCT)
Prior art keywords
lateral sclerosis
amyotrophic lateral
treatment
extracellular vesicle
vesicle composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033123
Other languages
French (fr)
Other versions
WO2024254540A2 (en
Inventor
Timothy Alexander Moseley
Kenneth Allen PETTINE
Joshua J. CROSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Direct Biologics LLC
Original Assignee
Direct Biologics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics LLC filed Critical Direct Biologics LLC
Priority to CN202480051907.2A priority Critical patent/CN121729236A/en
Publication of WO2024254540A2 publication Critical patent/WO2024254540A2/en
Publication of WO2024254540A3 publication Critical patent/WO2024254540A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are methods of treating amyotrophic lateral sclerosis in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.
PCT/US2024/033123 2023-06-09 2024-06-07 Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition Pending WO2024254540A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480051907.2A CN121729236A (en) 2023-06-09 2024-06-07 Amyotrophic Lateral Sclerosis Treatment Using Extracellular Vesicle Composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363507204P 2023-06-09 2023-06-09
US63/507,204 2023-06-09
US202463570632P 2024-03-27 2024-03-27
US63/570,632 2024-03-27

Publications (2)

Publication Number Publication Date
WO2024254540A2 WO2024254540A2 (en) 2024-12-12
WO2024254540A3 true WO2024254540A3 (en) 2025-02-20

Family

ID=93796466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033123 Pending WO2024254540A2 (en) 2023-06-09 2024-06-07 Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition

Country Status (2)

Country Link
CN (1) CN121729236A (en)
WO (1) WO2024254540A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
EP3920946A4 (en) 2019-02-07 2022-11-09 Direct Biologics LLC Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
MX2022013301A (en) 2020-04-22 2023-02-14 Direct Biologics Llc METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS ASSOCIATED WITH AN INFECTIOUS DISEASE.
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269739A1 (en) * 2016-11-03 2019-09-05 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
US20200316226A1 (en) * 2017-12-20 2020-10-08 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US20210128627A1 (en) * 2016-07-18 2021-05-06 Brainstorm Cell Therapeutics Ltd. Methods for treating amyotrophic lateral sclerosis (als)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210128627A1 (en) * 2016-07-18 2021-05-06 Brainstorm Cell Therapeutics Ltd. Methods for treating amyotrophic lateral sclerosis (als)
US20190269739A1 (en) * 2016-11-03 2019-09-05 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
US20200316226A1 (en) * 2017-12-20 2020-10-08 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery

Also Published As

Publication number Publication date
CN121729236A (en) 2026-03-24
WO2024254540A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2024254540A3 (en) Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition
WO2024254459A3 (en) Treatment of complex regional pain syndrome with extracellular vesicle composition
CN113041184B (en) Shampoo and preparation method thereof
CA3063540A1 (en) Compositions and methods for preventing, slowing, and reversing skin aging
KR101425716B1 (en) Novel Strain of Lactobacillus fermentum spp., Cosmetic Composition Using the same and Preparation Method thereof
ATE270323T1 (en) COMPOSITIONS AND METHODS FOR STIMULATING PROLIFERATION AND DIFFERENTIATION OF HUMAN FETAL AND ADULT PANCREATIC CELLS EX VIVO
ZA200900444B (en) Thin film multilocular structure comprising collagen, material for tissue regeneration containing the same and method for producing the same
WO2025189128A8 (en) Treatment of infertility with extracellular vesicle composition
MX2024014121A (en) Methods and compositions for treating glucocorticoid excess
BR112014028551A2 (en) culture medium for bacteria of the genus clostridium free of components of animal origin and process for the production of supernatant containing one or more proteases with collagenolytic and gelatinolytic activity
IL317920A (en) Method for producing nonhuman primate animal model of cerebral infarction and pharmaceutical composition for treatment of cerebral infarction
JP7297021B2 (en) Wound care composition containing lactic acid bacteria fermentation product
CN104490727B (en) The composition and application of a kind of stem cell and sodium hyaluronate
WO2023007244A1 (en) Mammalian cell population useful in cell therapy
US10842735B2 (en) Hair growth-promoting composition
KR102588400B1 (en) Mesenchymal stem cell culture media for preventing or treating immune disease and a method for preparing the same
CN117535237A (en) Human umbilical cord mesenchymal stem cell culture medium and preparation method thereof
CN105168092A (en) Cleansing composition with moisturizing and whitening function and preparation method thereof
WO2023067394A3 (en) Methods for making extracellular vesicles, and compositions and methods of use thereof
WO1996017627A3 (en) System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells
WO2003072128A8 (en) Methods and compositions for treating bone or cartilage defects
MX2025003509A (en) Human hair follicle-derived conditioned media and methods of making same
WO2025133708A2 (en) Therapeutic use of compositions and methods for epidermal treatment
CN121337857A (en) Uses of Lactobacillus fermentum GKF3 in the preparation of topical compositions that promote skin wound healing and provide antioxidant effects.
CN117503679A (en) Stem cell compositions and kits for beauty treatments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820188

Country of ref document: EP

Kind code of ref document: A2

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820188

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024820188

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109